^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    IRS2 amplification

    i
    Other names: IRS2, Insulin Receptor Substrate 2, IRS-2
    Entrez ID:
    8660
    Related biomarkers:
    Mutation
    Others
    over1year
    Pleomorphic giant cell carcinoma of the prostate: clinicopathologic analysis and oncological outcomes. (PubMed, Virchows Arch)
    Molecular alterations in 3 samples showed a microsatellite-stable disease with low tumor mutation burden and variable PTEN, PTCH1, KDM6A, ARv7, and PIK3CA loss/alteration, TP53 mutation, TMPRSS2-ERG fusion, and MYC, PIK3CB, RICTOR, or IRS2 amplification. Our findings suggest that PGCC is a rare and aggressive subtype of prostate carcinoma whose recognition may steer clinicians to adopt more aggressive treatments and investigate new therapeutic strategies.
    Journal • Tumor mutational burden
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • PTEN (Phosphatase and tensin homolog) • AR (Androgen receptor) • PTCH1 (Patched 1) • KDM6A (Lysine Demethylase 6A) • PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) • ERG (ETS Transcription Factor ERG) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • IRS2 (Insulin receptor substrate 2)
    |
    TP53 mutation • PIK3CA mutation • PTEN mutation • TMB-L • PTCH1 mutation • AR splice variant 7 • TMPRSS2-ERG fusion • IRS2 amplification